{"id":700,"date":"1998-04-01T12:03:00","date_gmt":"1998-04-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/vergleich-der-wirkung-von-omeprazol-ranitidin-und-misoprostol-bei-gastroduodenalen-ulzera-unter-nsaid-behandlung"},"modified":"1998-04-01T12:03:00","modified_gmt":"1998-04-01T10:03:00","slug":"vergleich-der-wirkung-von-omeprazol-ranitidin-und-misoprostol-bei-gastroduodenalen-ulzera-unter-nsaid-behandlung","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/vergleich-der-wirkung-von-omeprazol-ranitidin-und-misoprostol-bei-gastroduodenalen-ulzera-unter-nsaid-behandlung","title":{"rendered":"Vergleich der Wirkung von Omeprazol, Ranitidin und Misoprostol bei gastroduodenalen Ulzera unter NSAID-Behandlung"},"content":{"rendered":"<p>Viele Patienten, die dauerhaft nichtsteroidale Antirheumatika (NSAID) einnehmen m\u00fcssen, entwickeln, z.T. asymptomatisch, Magen- und Duodenal-Ulzera und\/oder -Erosionen. Yeomans, N.D., et al. (1) und Hawkey, C.J., (2) et al. untersuchten in einer multizentrischen, multinationalen Studie die Wirkung von Omeprazol, Ranitidin und Misoprostol auf solche Ulzera\/Erosionen. In die Studie von Yeomans, N.D., et al. wurden 541 Patienten [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viele Patienten, die dauerhaft nichtsteroidale Antirheumatika (NSAID) einnehmen m\u00fcssen, entwickeln, z.T. asymptomatisch, Magen- und Duodenal-Ulzera und\/oder -Erosionen. Yeomans, N.D., et al. (1) und Hawkey, C.J., (2) et al. untersuchten in einer multizentrischen, multinationalen Studie die Wirkung von Omeprazol, Ranitidin und Misoprostol auf solche Ulzera\/Erosionen. In die Studie von Yeomans, N.D., et al. wurden 541 Patienten [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1805,648,649,1806,564,562,563,565,111,1807,115,114,583,106,104],"class_list":["post-700","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-astronaut-studie","tag-h2-rezeptor-antagonisten","tag-h2-rezeptoren-blocker","tag-misoprostol","tag-nichtsteroidale-antiphlogistika","tag-nichtsteroidale-antirheumatika","tag-nsaid","tag-nsar","tag-omeprazol","tag-omnium-studie","tag-protonenpumpen-hemmer","tag-protonenpumpenhemmer","tag-ranitidin","tag-ulcus-duodeni","tag-ulcus-ventriculi"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=700"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/700\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}